Published in

Wiley, British Journal of Dermatology, 5(153), p. 869-873, 2005

DOI: 10.1111/j.1365-2133.2005.06880.x

Links

Tools

Export citation

Search in Google Scholar

The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.

Journal article published in 2005 by R. B. Warren, C. E. M. Griffiths ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The study of pharmacogenetics will optimize the use of systemic therapies in dermatology. Directed prescription of azathioprine dependent on phenotypic expression of the thiopurine methyltransferase gene is now accepted practice. To some extent other, older drugs have been neglected. We look at the role that pharmacogenetics could play in the use of methotrexate for psoriasis, focusing on known polymorphisms in the folate metabolic pathway.